Antibody-Drug Conjugates (ADCs) have been proposed for more than four decades, and numerous scientists have continued to optimize antibodies, cytotoxic payloads, linkers, clinical assays, and clinical trial protocols, ushering in a bumper crop in the last two years with the FDA approval of several ADC drugs.
The targets of approved and pipeline ADC drugs are mainly classical targets, such as HER2 and BCMA. However, new targets have been emerging in recent years.
1. Folate receptor alpha (FRα)
Folate receptor alpha (FRα), highly expressed in solid tumors, such as mesothelioma (72-100%), triple-negative breast cancer (35-68%), ovarian cancer (76-89%), and non-small cell lung cancer (14-74%), is involved in tumor infiltration, metastasis, and progression, making it an attractive target for tumor therapy.
FRα expression, image source: Nat Rev Clin Oncol . 2020 Jun;17(6):349-359.
Eisai acquired the FRα monoclonal antibody Farletuzumab through the acquisition of Morphotek. However, Phase 3 clinical data published in 2016 for Farletuzumab in patients with platinum-resistant ovarian cancer showed that it did not meet the primary design endpoint of PFS. subsequently, Eisai developed the ADC drug MORAb-202 (farletuzumab and eribulin conjugated) with favorable preclinical data and two clinical studies underway (NCT04300556, NCT03386942). On June 17, BMS made a $650 million down payment to enter into a co-development agreement with Eisai.
Mirvetuximab soravtansine (IMGN853) was developed by ImmunoGen with the cytotoxic drug DM4 linked to a humanized anti-FRα monoclonal antibody by a cleavable linker.It was granted orphan drug designation for the treatment of ovarian cancer in the EU in April 2015 and in the US in August 2014. in June 2018, the US FDA granted Fast Track designation to this ADC drug.
The Phase 3 clinical FORWARD I study of mirvetuximab soravtansine (NCT02631876) showed that the primary endpoint was not met, but efficacy was demonstrated. After consultation with the FDA, ImmunoGen initiated two new Phase 3 clinical studies, the SORAYA study (NCT04296890); and the MIRASOL study (NCT04209855), focused on platinum-resistant, high FRα-expressing ovarian cancer patients, with results expected in late 2021 or 2022.
2. Tissue Factor (TF)
Tissue factor (TF), a transmembrane glycoprotein expressed by subendothelial cells and fibroblasts, plays an important role in hemostasis regulation. Various factors of tumor microenvironment such as hypoxia and TGF-β upregulate TF expression in tumor cells, and TF can promote tumor growth, angiogenesis, metastasis and thrombosis.
Tissue factor transcription, image source: BLOOD, 26 JANUARY 2012
Tisotumab vedotin, also known as TIVDAK, jointly developed by Seagen and Genmab, is an ADC targeted to Tissue Factor (TF). It includes an antibody targeting Tissue Factor (TF) conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. On September 20, 2021, it is approved by FDA for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
LIV-1 is a transmembrane protein with zinc transporter and metalloproteinase activity. Their expression in tissues is heterogeneous, reflecting their different functions. Among them, the LIV1 (ZIP6) protein is mainly expressed in hormone-controlled tissues and its expression is sensitive to estrogen levels. It was first identified as an estrogen-inducible gene in breast cancer cell lines and subsequently found to be associated with HR-positive breast cancers. In addition to breast cancer, it has also been detected in pancreatic, prostate, melanoma, cervical and uterine cancers.
Ladiratuzumab vedotin (SGN-LIV1A), developed by Seagen, is a humanized antibody conjugated through a proteolytically cleavable linker to MMAE to Zinc transporter LIV-1 (SLC39A6).
Ladiratuzumab vedotinc pipeline, image source: Seagen official website
A phase 1 clinical trial in breast cancer (NCT01969643) has been conducted with a planned enrollment of 508 patients. Early results were observed in 69 metastatic breast cancers with overall good treatment performance and a toxicity profile similar to other MMAE-based ADCs. Major adverse effects included fatigue (59%), nausea (51%), peripheral neuropathy (44%), alopecia (36%), decreased appetite (33%), constipation (30%), abdominal pain (25%), diarrhea (25%), and neutropenia (25%). Neutropenia (25%) and anemia (15%) were ≥ grade 3. Preliminary antitumor activity was observed in both the HR+/HER2- (DCR 59%) and TNBC (DCR 64%) subgroups. Notably, the LIV1 expression rate was 91% in 631 tumor samples, with moderate to high expression in 75% of cases.
SGN-LIV1A can also induce immunogenic cell death (ICD), which may increase the effectiveness of immunotherapy. A Phase 1/2 clinical trial (NCT03310957) is underway in combination with Pembrolizumab for the treatment of advanced breast cancer or metastatic triple negative breast cancer.
In addition, a Phase 2 clinical trial (NCT04032704) in multiple solid tumors is enrolling patients.
Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) are a family of 12 immunoglobulin-associated proteins that are physiologically expressed on the cell membranes of many epithelial tissues and they act as regulators of different processes such as cell adhesion, differentiation, proliferation and survival.
There is a close relationship between CEACAMs and cancer, and CEA (CEACAM5) was found to be a tumor biomarker, in addition to being involved in the signaling regulation of cancer progression and metastasis. Drugs targeting CEACAM1, CEACACAM5 or CEACAM6 are already in development. In particular, CEACAM5 is highly expressed in several tumors, including CRC, lung and gastric tumors, and has become a major target for ADC drug development.
SAR408701 is a novel ADC developed by Sanofi, which consists of an anti-CEACAM5 antibody (SAR408377) coupled to DM4, a maytansinoid agent.
First-in-human phase I trial of the SAR408701 enrolled 31 patients with advanced solid tumors (NCT02187848), including patients with colorectal cancer (18), gastric cancer (7), adenocarcinoma of the gastroesophageal junction (3), esophageal cancer (1), breast cancer (1), and pancreatic cancer (1). CEACAM5 expression was evaluated retrospectively by IHC. The most common adverse events (≥20%) were fatigue/weakness (32%), nausea and decreased appetite (26%), diarrhea, constipation, and keratoconus (23%). dose-limiting toxicities (DLTs) occurred in five patients with a maximum tolerated dose (MTD) at 100 mg/m2Q2W. SAR408701 was subsequently recruited in three extended cohorts of patients with colorectal cancer, lung cancer (small cell lung cancer and non-squamous NSCLC), and gastric cancer. The most promising data came from the nonsquamous NSCLC cohort, where high antitumor activity was particularly high in patients expressing CEACAM5 (≥50%; ORR 20.3%, SD 42.2%), while response was reduced in those with moderate expression (1-49%; ORR 7.1%). Therefore, subsequent development of SAR408701 is focused on patients with CEACAM5-positive non-squamous NSCLC with three ongoing clinical studies: monotherapy (CARMEN-LC03), in combination with ramucirumab monoclonal antibody (CARMEN-LC04) or in combination with PD-1 (CARMEN-LC05).
Labetuzumab govitecan (IMMU-130), developed by GileadSciences, is consisting of Labetuzumab (CEACACAM5 antibody) coupled to SN-38. Due to unsatisfactory preclinical results, there are now no clinical studies underway.
ADC drugs have gained rapid development in the past two years. In addition to classical targets such as HER2, new targets such as folate receptor, tissue factor, LIV-1 and CEACAM have also made positive progress. Both folate receptor and tissue factor have drugs in clinical phase III, and Tisotumab vedotin has already submitted BLA, and it is believed that there will be new drugs in ADC field in the next two years. In addition to the above targets, ADCs for targets such as HER3, Mesothelin, and c-Met are also starting to enter clinical phase 1/2.
Biochempeg is dedicated to being your most reliable partner to provide chemical synthesis and high-quality PEG linkers. We are committed to promoting the progress of your ADC discovery and development projects.
 Vergote, I. et al. Arandomized, double- blind, placebo- controlled, phase III study to assessefficacy and safety of weekly farletuzumab in combination with carboplatin andtaxane in patients with ovarian cancer in first platinum- sensitive relapse. J.Clin. Oncol. 34, 2271–2278 (2016).
 Mariana Scaranti et al，Exploiting the folate receptor α in oncology，Nat Rev Clin Oncol . 2020 Jun;17(6):349-359.
 Taylor KM, Morgan HE, Smart K,Zahari NM, Pumford S, Ellis IO, Robertson JFR, Nicholson RI. The emerging roleof the LIV-1 subfamily of zinc transporters in breast cancer. Mol Med.2007;13:396–406.
 Modi S, Pusztai L, Forero A,et al. Abstract PD3–14: phase 1 study of the antibody-drug conjugate SGN-LIV1Ain patients with heavily pretreated triple-negative metastatic breast cancer.Cancer Res. 2018;78:PD3-14-PD3-14.
 Gazzah A, Stjepanovic N, RyuMH, et al. First-in-human phase I trial of the anti-CEACAM5 antibody-drugconjugate SAR408701 in patients with advanced solid tumors (NCT02187848). Eur JCancer. 2016;69:S14–5.
 Gazzah A, Ricordel C, Cousin S,et al. Efcacy and safety of the antibodydrug conjugate (ADC) SAR408701 inpatients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC)expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).J Clin Oncol. 2020;38:9505–9505.
11 FDA Approved Antibody-Drug Conjugates: An Overview
History and Development of Antibody Drug Conjugates (ADCs)
Cleavable vs. Non-Cleavable Linkers in Antibody-Drug Conjugates